Image 01 Image 03

Wuhan Coronavirus Tag

AstraZeneca announced Monday morning its COVID-19 vaccine, AZD1222, given in the United Kingdom and Brazil showed 90% effectiveness in preventing the virus after half a dose and then a full dose one month later. It is only 62% effective if given two full doses a month apart. The trial had 23,000 volunteers.

Pfizer and BioNTech found its COVID-19 is 95% effective in the last trial run, "meeting all primary efficacy endpoints." The vaccine also showed signs of safety and met all the requirements for the FDA to approve its use as soon as possible.